Foresee Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Foresee Pharmaceuticals is Ben Chien, benoemd in Mar2021, heeft een ambtstermijn van 3.67 jaar. bezit rechtstreeks 0.68% van de aandelen van het bedrijf, ter waarde NT$ 72.07M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.1 jaar en 8.7 jaar.

Belangrijke informatie

Ben Chien

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	3.7yrs
Eigendom CEO	0.7%
Management gemiddelde ambtstermijn	4.1yrs
Gemiddelde ambtstermijn bestuur	8.7yrs

Recente managementupdates

Recent updates

We Might See A Profit From Foresee Pharmaceuticals Co., Ltd. (GTSM:6576) Soon

Mar 24

Investors Who Bought Foresee Pharmaceuticals (GTSM:6576) Shares A Year Ago Are Now Up 41%

Dec 22

Analyse CEO-vergoeding

Hoe is Ben Chien's beloning veranderd ten opzichte van Foresee Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-NT$859m
Mar 31 2024	n/a	n/a	-NT$977m
Dec 31 2023	n/a	n/a	-NT$1b
Sep 30 2023	n/a	n/a	-NT$906m
Jun 30 2023	n/a	n/a	-NT$833m
Mar 31 2023	n/a	n/a	-NT$530m
Dec 31 2022	NT$16m	NT$12m	-NT$473m
Sep 30 2022	n/a	n/a	-NT$458m
Jun 30 2022	n/a	n/a	-NT$467m
Mar 31 2022	n/a	n/a	-NT$532m
Dec 31 2021	NT$12m	NT$10m	-NT$569m
Sep 30 2021	n/a	n/a	-NT$429m
Jun 30 2021	n/a	n/a	-NT$458m
Mar 31 2021	n/a	n/a	-NT$560m
Dec 31 2020	NT$8m	NT$8m	-NT$511m
Sep 30 2020	n/a	n/a	-NT$546m
Jun 30 2020	n/a	n/a	-NT$527m
Mar 31 2020	n/a	n/a	-NT$556m
Dec 31 2019	NT$12m	NT$7m	-NT$487m
Sep 30 2019	n/a	n/a	-NT$568m
Jun 30 2019	n/a	n/a	-NT$511m
Mar 31 2019	n/a	n/a	-NT$489m
Dec 31 2018	NT$9m	n/a	-NT$552m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Ben redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de TW markt.

Compensatie versus inkomsten: De vergoeding van Ben is gestegen terwijl het bedrijf verliesgevend is.

CEO

Ben Chien

3.7yrs

Tenure

NT$16,166,000

Compensatie

Dr. Benjamin Chien, also known as Ben, Ph.D. Founded Foresee Pharmaceuticals Co., Ltd. and serves as its Chairman. Dr. Chien served as President at Foresee Pharmaceuticals Co., Ltd.since March 25, 2021 un...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Benjamin Chien	Founder	3.7yrs	NT$16.17m	0.68% NT$ 72.1m
Yuhua Li	Co-founder & Chief Technology Officer	no data	NT$3.06m	0.42% NT$ 44.9m
Mathieu Boudreau	Chief Business Officer & Chief Operating Officer	no data	NT$585.00k	geen gegevens
Wenjin Yang	Chief Scientific Officer	9.2yrs	NT$4.99m	0.085% NT$ 9.0m
Yisheng Lee	Chief Medical Officer & Director	no data	NT$1.99m	0.56% NT$ 59.3m
Jagdish Parasrampuria	Senior Vice President of Pharmaceutics & Manufacturing	3.9yrs	NT$5.46m	0.058% NT$ 6.2m
MengKung Chan	Chief Financial Officer	5.1yrs	geen gegevens	0.12% NT$ 13.3m
Liang Chris	Accounting Officer	less than a year	geen gegevens	geen gegevens
John Mao	Consultant	4.3yrs	geen gegevens	geen gegevens
Peifen Chou	Consultant	6yrs	geen gegevens	geen gegevens
Bassem Elmankabadi	Senior Vice President of Clinical Development	1.6yrs	geen gegevens	0.029% NT$ 3.1m

4.1yrs

Gemiddelde duur

Ervaren management: Het managementteam van 6576 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Benjamin Chien	Founder	11.8yrs	NT$16.17m	0.68% NT$ 72.1m
Yisheng Lee	Chief Medical Officer & Director	11.8yrs	NT$1.99m	0.56% NT$ 59.3m
Jia-Long Lee	Director	9.3yrs	NT$25.00k	0.036% NT$ 3.8m
Eric Gordon	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Daria Mochly-Rosen	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Vincent Yen	Representative Director	11.8yrs	NT$35.00k	0.063% NT$ 6.7m
Fu-Shiow Yin	Independent Director	8.7yrs	NT$440.00k	geen gegevens
Joseph Vacca	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jeff Wang	Director	8.7yrs	NT$35.00k	0.0095% NT$ 1.0m
Hank Lai	Independent Director	6.4yrs	NT$440.00k	geen gegevens
Wen-Chi Lee	Independent Director	8.7yrs	NT$440.00k	0.082% NT$ 8.8m
Ben Liu	Independent Director	1.4yrs	geen gegevens	geen gegevens

8.7yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van 6576 wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.7 jaar).

Foresee Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Ben Liu as Independent Director

Less than half of directors are independent

Foresee Pharmaceuticals Co., Ltd. Approves Appointment of Max Chan as Corporate Governance Officer

Less than half of directors are independent

Recent updates

Foresee Pharmaceuticals Receives the Second Positive Recommendation from DSMB to Continue the Casppian Study

Foresee Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Nov 13, 2024

Foresee Pharmaceuticals Co., Ltd. Announces Submission of the NDA to the U.S. FDA for the 3-month Version of CAMCEVI for the Treatment of Advanced Prostate Cancer

Foresee Pharmaceuticals Co., Ltd. Announces on Behalf of Subsidiary, Foresee Pharmaceuticals Australia Pty Ltd, the Preliminary Results from the Linvemastat (Fp-020) Phase 1 Trial

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Foresee Pharmaceuticals Co., Ltd. Announces Several New Developments Related to its SIF Long-Acting Injectable (LAI) Technologies - Solidifying its Position as a Leader in Complex Long-Acting Injectability Products

Foresee Pharmaceuticals Co., Ltd. to Report Q2, 2024 Results on Aug 14, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Foresee Pharmaceuticals Announces First Subject Dosed in Its First-In-Human Clinical Trial of FP-020

Foresee Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on May 03, 2024

Foresee Pharmaceuticals Receives Positive Recommendation from Data and Safety Monitoring Board to Continue the Casppian Study

Full year 2023 earnings: EPS misses analyst expectations

Foresee Pharmaceuticals Co., Ltd. has filed a Follow-on Equity Offering.

Consensus revenue estimates fall by 38%

Foresee Pharmaceuticals Co., Ltd. Announces Last Patient Enrolled in the China Registration Clinical Trial of Leuprolide Injectable Emulsion in Prostate Cancer Has Completed Treatment

Foresee Pharmaceuticals Co., Ltd. Submits Phase 3 IND (Investigational New Drug) Application to China NMPA

Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion, 42 mg for the Treatment of Central Precocious Puberty Patients

Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 Activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium

New minor risk - Shareholder dilution

Foresee Pharmaceuticals Announces FDA Orange Book Listing of New U.S. Patent for Camcevi®, Extending Patent Protection to 2039

New minor risk - Revenue size

Second quarter 2023 earnings: Revenues miss analyst expectations

Forecast to breakeven in 2024

Price target decreased by 12% to NT$122

No longer forecast to breakeven

Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Ben Liu as Independent Director

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Foresee Pharmaceuticals Co., Ltd. Receives Approval from China NMPA for the Application of Phase 3 IND for FP-001 42 mg in Patients with Central Precocious Puberty

Foresee Pharmaceuticals Co., Ltd. Receives Approval from Taiwan FDA for the Application of Phase 3 IND for FP-001 42 Mgin Patients with Central Precocious Puberty

Foresee Pharmaceuticals Co., Ltd. Announces the Submission of A Phase 3 Clinical Trial Application for FP-001 42 Mg in Patients with Central Precocious Puberty to EMA

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Foresee Pharmaceuticals Co., Ltd. Announces Phase 3 Clinical Trial Application for Fp-00142 Mg in Patients with Central Precocious Puberty Has Been Accepted by China NMPA for Substantial Review

Consensus revenue estimates fall by 32%

Foresee Pharmaceuticals Co., Ltd. Proceeds with FP-001 42 Mg Phase 3 Clinical Trial in Patients with Central Precocious Puberty

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Foresee Pharmaceuticals Co., Ltd. Submits IND for FP-045 in Patientswith Fanconi Anemia by TRPharm to the Ministry of Health of Turkey

Foresee Announces Phase 2 Results of FP-025 Inpatients with Covid-19 Associated ARDS

Forecast to breakeven in 2024

Foresee Pharmaceuticals Announces European Commission Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer

First quarter 2022 earnings released: NT$1.04 loss per share (vs NT$1.36 loss in 1Q 2021)

Foresee Pharmaceuticals Co., Ltd. Approves Appointment of Max Chan as Corporate Governance Officer

Israel Accepts for Substantial Review of Marketing Authorization Application for CAMCEVI 42 mg of Foresee Pharmaceuticals Co., Ltd

Price target increased to NT$130

Less than half of directors are independent

Accord BioPharma in Partnership with Foresee Pharmaceuticals Co., Ltd., the U.S. Launch of CAMCEVI (Leuprolide) 42Mg Injection Emulsion for the Treatment of Advanced Prostate Cancer in Adults

Full year 2021 earnings: EPS exceeds analyst expectations

No longer forecast to breakeven

Price target increased to NT$130

Consensus forecasts updated

Foresee Pharmaceuticals Co., Ltd. Announces Registration Clinical Trial Application for CAMCEVI42 Mg Accepted by China NMPA for Substantial Review

Foresee Pharmaceuticals Co., Ltd. Announces Positive Recommendation from Second IDMC Review Meeting to Continue FP-025 Covid-19/ARDS Phase 2/3 Study

Tolmar Files Complaint Against Foresee Pharmaceuticals Co., Ltd. for Patent Infringement

Foresee Announces Positive Recommendation from IDMCPhase 2 Safety Review Meeting to Continue FP-02 Covid-19/ARDS Phase 2/3 Study Without Change

Price target increased to NT$125

Foresee Pharmaceuticals Co., Ltd. Announces FDA Approval of CAMCEVI 42 mg for the Treatment of Advanced Prostate Cancer

Price target decreased to NT$112

First quarter 2021 earnings released: NT$1.36 loss per share (vs NT$1.10 loss in 1Q 2020)

Senior Director & Head of QA has left the company

We Might See A Profit From Foresee Pharmaceuticals Co., Ltd. (GTSM:6576) Soon

New 90-day high: NT$107

Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States

Foresee Received Notification from US FDA That Itmay Proceed with the FP-025 Phase 2/3 Clinical Trials Inpatients with COVID-19 Associated ARDS

Price target lowered to NT$123

Foresee Pharmaceuticals Co., Ltd. announced that it has received TWD 90 million in funding

Foresee Pharmaceuticals Co., Ltd. has completed a Follow-on Equity Offering in the amount of TWD 1.32 billion.

Investors Who Bought Foresee Pharmaceuticals (GTSM:6576) Shares A Year Ago Are Now Up 41%

Foresee Pharmaceuticals Enters Into Exclusive License Agreement with GenScience Pharmaceuticals for the Commercialization of Camcevi(TM) in China

New 90-day high: NT$102

Earnings miss expectations

Foresee Pharmaceuticals Co., Ltd. Announces New Drug Application for FP-001 LMIS 50mg Accepted for Review by the U.S. Food and Drug Administration